877 related articles for article (PubMed ID: 24577124)
21. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
22. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
[TBL] [Abstract][Full Text] [Related]
23. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
24. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
Mani H; Hesse C; Stratmann G; Lindhoff-Last E
Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
[TBL] [Abstract][Full Text] [Related]
26. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
28. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J; Mullier F; Loosen C; Chatelain C; Chatelain B; Dogné JM
Thromb Res; 2012 Dec; 130(6):956-66. PubMed ID: 23006523
[TBL] [Abstract][Full Text] [Related]
30. Warfarin replacements: good for patients, challenging for laboratories.
Eby CS
Clin Chem; 2013 May; 59(5):732-4. PubMed ID: 23487173
[No Abstract] [Full Text] [Related]
31. [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P
Ann Fr Anesth Reanim; 2013 Oct; 32(10):691-700. PubMed ID: 23993157
[TBL] [Abstract][Full Text] [Related]
32. Coagulation Testing in the Core Laboratory.
Winter WE; Flax SD; Harris NS
Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Zylla MM; Pohlmeier M; Hess A; Mereles D; Kieser M; Bruckner T; Scholz E; Zitron E; Schweizer PA; Katus HA; Thomas D
Am J Cardiol; 2015 Mar; 115(5):635-40. PubMed ID: 25591898
[TBL] [Abstract][Full Text] [Related]
34. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Mani H; Hesse C; Stratmann G; Lindhoff-Last E
Thromb Haemost; 2011 Jul; 106(1):156-64. PubMed ID: 21655672
[TBL] [Abstract][Full Text] [Related]
35. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
36. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
37. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
Freyburger G; Macouillard G; Labrouche S; Sztark F
Thromb Res; 2011 May; 127(5):457-65. PubMed ID: 21277622
[TBL] [Abstract][Full Text] [Related]
38. Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Baruch L
Postgrad Med; 2013 Mar; 125(2):135-45. PubMed ID: 23816779
[TBL] [Abstract][Full Text] [Related]
39. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
40. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]